Literature DB >> 23296566

Computational study and peptide inhibitors design for the CDK9 - cyclin T1 complex.

Jelena Randjelović1, Slavica Erić, Vladimir Savić.   

Abstract

Cyclin dependent kinase 9 (CDK9) is a protein that belongs to the cyclin-dependent kinases family, and its main role is in the regulation of the cell transcription processes. Since the increased activity of CDK9 is connected with the development of pathological processes such as tumor growth and survival and HIV-1 replication, inhibition of the CDK9 could be of particular interest for treating such diseases. The activation of CDK9 is initiated by the formation of CDK9/cyclin T1 complex, therefore disruption of its formation could be a promising strategy for the design of CDK9 inhibitors. In order to assist in the design of potential inhibitors of CDK9/cyclin T1 complex formation, a computational study of the CDK9/cyclin T1 interface was conducted. Ten peptides were designed using the information from the analysis of the complex, hot spot residues and fragment based design. The designed peptides were docked to CDK9 structures obtained by molecular dynamics simulations of CDK9/cyclin T1 complex and the CDK9 alone and their binding affinities were evaluated using molecular mechanics Poisson Boltzman surface area (MM-PBSA) method and steered molecular dynamics (SMD). Designed peptide sequences LQTLGF and ESIILQ, both derived from the surface of cyclin T1, as well as the peptide sequence PRWPE, derived from fragment based design, showed the most favorable binding properties and were selected for our further studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23296566     DOI: 10.1007/s00894-012-1735-2

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  55 in total

1.  The penultimate rotamer library.

Authors:  S C Lovell; J M Word; J S Richardson; D C Richardson
Journal:  Proteins       Date:  2000-08-15

2.  Single-molecule pulling simulations can discern active from inactive enzyme inhibitors.

Authors:  Francesco Colizzi; Remo Perozzo; Leonardo Scapozza; Maurizio Recanatini; Andrea Cavalli
Journal:  J Am Chem Soc       Date:  2010-06-02       Impact factor: 15.419

3.  PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions.

Authors:  Mats H M Olsson; Chresten R Søndergaard; Michal Rostkowski; Jan H Jensen
Journal:  J Chem Theory Comput       Date:  2011-01-06       Impact factor: 6.006

4.  Comparison of multiple Amber force fields and development of improved protein backbone parameters.

Authors:  Viktor Hornak; Robert Abel; Asim Okur; Bentley Strockbine; Adrian Roitberg; Carlos Simmerling
Journal:  Proteins       Date:  2006-11-15

5.  Effect of two simultaneous aza-β3-amino acid substitutions on recognition of peptide substrates by cAMP dependent protein kinase catalytic subunit.

Authors:  Ksenija Kisseljova; Aleksei Kuznetsov; Michèle Baudy-Floc'h; Jaak Järv
Journal:  Bioorg Chem       Date:  2011-05-07       Impact factor: 5.275

6.  Crystal structure of HIV-1 Tat complexed with human P-TEFb.

Authors:  Tahir H Tahirov; Nigar D Babayeva; Katayoun Varzavand; Jeffrey J Cooper; Stanley C Sedore; David H Price
Journal:  Nature       Date:  2010-06-10       Impact factor: 49.962

7.  Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes.

Authors:  Dominic Salerno; Muneer G Hasham; Renée Marshall; Judit Garriga; Alexander Y Tsygankov; Xavier Graña
Journal:  Gene       Date:  2007-09-19       Impact factor: 3.688

8.  CDK9 has the intrinsic property to shuttle between nucleus and cytoplasm, and enhanced expression of cyclin T1 promotes its nuclear localization.

Authors:  Giuliana Napolitano; Paolo Licciardo; Roberta Carbone; Barbara Majello; Luigi Lania
Journal:  J Cell Physiol       Date:  2002-08       Impact factor: 6.384

9.  Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1).

Authors:  Ya-Lin Chiu; Hong Cao; Jean-Marc Jacque; Mario Stevenson; Tariq M Rana
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

Review 10.  Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.

Authors:  Vladimír Krystof; Sonja Baumli; Robert Fürst
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

View more
  5 in total

1.  Molecular analysis of the interaction between staphylococcal virulence factor Sbi-IV and complement C3d.

Authors:  Ronald D Gorham; Wilson Rodriguez; Dimitrios Morikis
Journal:  Biophys J       Date:  2014-03-04       Impact factor: 4.033

Review 2.  Overview of CDK9 as a target in cancer research.

Authors:  Fatima Morales; Antonio Giordano
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

3.  Evaluation of peptide designing strategy against subunit reassociation in mucin 1: A steered molecular dynamics approach.

Authors:  J Lesitha Jeeva Kumari; R Jesu Jaya Sudan; C Sudandiradoss
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

4.  Inhibition of the CDK9-cyclin T1 protein-protein interaction as a new approach against triple-negative breast cancer.

Authors:  Sha-Sha Cheng; Yuan-Qing Qu; Jia Wu; Guan-Jun Yang; Hao Liu; Wanhe Wang; Qi Huang; Feng Chen; Guodong Li; Chun-Yuen Wong; Vincent Kam Wai Wong; Dik-Lung Ma; Chung-Hang Leung
Journal:  Acta Pharm Sin B       Date:  2021-10-30       Impact factor: 14.903

5.  Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein-protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells.

Authors:  Shasha Cheng; Guan-Jun Yang; Wanhe Wang; Dik-Lung Ma; Chung-Hang Leung
Journal:  Genes Dis       Date:  2021-07-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.